“…For example, because many tumor cells, including melanoma, that are targets for gene therapy express no or little CAR, it is difficult to achieve sufficient gene expression and therapeutic effect (Okada et al, 2003b;Mathis et al, 2006). Reduced expression of CAR in advanced tumor stages is one of the major obstacles to the use of Adv for cancer gene therapy (Yamamoto et al, 1997;Li et al, 1999;Yamashita et al, 2007). To overcome these problems, we developed Tat-modified Adv with broadened tropism and enhanced transduction efficiency.…”